Article

Migraine Patch May Cause Burns FDA Says

Author(s):

The US Food and Drug Administration is investigation the risk of burns in people who use the sumatriptan iontophoretic system, a device it approved in September.

Based on patient complaints, the US Food and Drug Administration is investigating the risk of burns in patients who use a transdermal patch containing sumatriptan (Zecuity/Teva) to treat migraine.

The patch delivers the medication through a single-use battery-powered patch placed on the upper arm or thigh.

It is supposed to be worn for no more than four hours.

The agency is advising patients who experience moderate to severe pain at the patch site to remove it and contact their physician.

Physicians should prescribe an alternative therapy and are encouraged to report these events to www.fda.gov/MedWatch/report.

The manufacturer lists several potential serious side effects with the patch, mostly assiociated with the affects of the drug itself, but burns is not among them.

Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Skin of Color Savvy: The Art and Science of Treating Patients of Color
Crisis Point: Benzene Concerns in Acne Care
© 2025 MJH Life Sciences

All rights reserved.